Alzamend Neuro, Inc.
ALZN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001677077
In the last 90 days, Alzamend Neuro, Inc. insiders filed 1 open-market purchase and 1 sale; 12 institutions reported holding it in 13F filings for Q2 2026, worth $3.26M in total; no superinvestor holds it.
Q4 2024 vs. Q3 2024
How the institutions holding Alzamend Neuro, Inc. changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 12 | 17 | +5 |
| Shares | 42.1K | 113.3K | +71.2K (+169.2%) |
| Value | $71.2K | $131.7K | +$60.6K (+85.1%) |
New holders (8)
Institutions that held Alzamend Neuro, Inc. at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Geode Capital Management, LLC | 33,540 | $38.9K | 0.00% |
| Citadel Advisors LLC | 30,638 | $35.5K | 0.00% |
| Renaissance Technologies LLC | 15,000 | $17.4K | 0.00% |
| Virtu Financial LLC | 12,719 | $15.0K | 0.00% |
| UBS Group AG | 820 | $951 | 0.00% |
| Citigroup Inc | 544 | $631 | 0.00% |
| SBI Securities Co., Ltd. | 18 | $21 | 0.00% |
| Advisor Group Holdings, Inc. | 6 | $7 | 0.00% |
Sold out (3)
Institutions that held Alzamend Neuro, Inc. at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Susquehanna International Group, LLP | 16,601 | $28.1K |
| Wells Fargo & Company | 1,000 | $1.69K |
| CoreCap Advisors, LLC | 708 | $1.20K |